{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T16:15:13Z","timestamp":1781799313713,"version":"3.54.5"},"reference-count":40,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2020,4,24]],"date-time":"2020-04-24T00:00:00Z","timestamp":1587686400000},"content-version":"unspecified","delay-in-days":23,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Intramural Research Program of the National Library of Medicine, National Institutes of Health"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Diab Res Care"],"accepted":{"date-parts":[[2020,3,21]]},"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Most patients with type 2 diabetes mellitus (T2DM) also have hypertension and hyperlipidemia. Consequently, they are taking medications for all three conditions concurrently and the effect of one drug could be confounded with that of another. This study aimed to determine the independent effects of 15 commonly prescribed medications for three conditions on the risk of all-cause mortality among elderly patients with T2DM.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Research design and methods<\/jats:title>\n                  <jats:p>A cohort of 360\u2009437 elderly patients with T2DM from 2007 to 2016 US Medicare data was traced along with cumulative uses of 8 diabetes, 6 hypertension and 1 hyperlipidemia drugs. The relative risk of all-cause mortality for each study drug was estimated using an extended Cox regression analysis adjusting for the concurrent use of other study drugs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Compared with the no use of each study medication, mortality risk declined with use of 3 diabetes drugs, sodium-glucose cotransporter-2 inhibitors (HR=0.73; 95%\u2009CI 0.64 to 0.84), glucagon-like peptide-1 receptor agonists (HR=0.75; 95%\u2009CI 0.70 to 0.80) and dipeptidyl peptidase-4 inhibitors (HR=0.94; 95%\u2009CI 0.91 to 0.98), the use of 3 blood pressure medications, diuretics (HR=0.89; 95%\u2009CI 0.87 to 0.92), angiotensin receptor blockers (HR=0.86; 95%\u2009CI 0.84 to 0.89), ACE inhibitors (HR=0.98; 95%\u2009CI 0.95 to 1.01) as well as statins (HR=0.83; 95%\u2009CI 0.80 to 0.85). It increased moderately with insulin (HR=1.55; 95%\u2009CI 1.51 to 1.59), sulfonylureas (HR=1.16; 95%\u2009CI 1.13 to 1.20), a small <jats:italic>inconsistent<\/jats:italic> amount with metformin (HR=1.05), beta-blockers (HR=1.07), dihydropyridine calcium-channel blockers (HR=0.99) and non-dihydropyridine calcium-channel blockers (HR=1.05). The use of thiazolidinedione had no effect.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Among older patients with diabetes, mortality risk <jats:italic>decreased<\/jats:italic> importantly with three new diabetes drugs, 3 blood pressure drugs and statins. It <jats:italic>increased<\/jats:italic> moderately with sulfonylurea and insulin. Studies of aggressive use of new T2DM drugs instead of sulfonylureas and insulin are needed. Our statin results empirically validate two national guidelines for using statins in older patients with diabetes. However, 23% of study patients never took a statin, suggesting missed opportunities for prevention.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjdrc-2019-000940","type":"journal-article","created":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T04:21:22Z","timestamp":1587961282000},"page":"e000940","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":14,"title":["Independent effects of 15 commonly prescribed drugs on all-cause mortality among US elderly patients with type 2 diabetes mellitus"],"prefix":"10.1136","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2077-4316","authenticated-orcid":false,"given":"Seo H","family":"Baik","sequence":"first","affiliation":[{"name":"Lister Hill National Center for Biomedical Communications, National Library of Medicine, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clement J","family":"McDonald","sequence":"additional","affiliation":[{"name":"Lister Hill National Center for Biomedical Communications, National Library of Medicine, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,4,26]]},"reference":[{"key":"2025073111431943000_8.1.e000940.1","doi-asserted-by":"publisher","DOI":"10.1186\/s12963-016-0110-4"},{"key":"2025073111431943000_8.1.e000940.2","unstructured":"The Center for Medicare & Medicaid Services. CMS.gov: CMS Announces New Data Sharing Tool, 2013. Available: https:\/\/www.cms.gov\/Newsroom\/MediaReleaseDatabase\/Press-releases\/2013-Press-releases-items\/2013-11-12.html [Accessed 23 Jan 2017]."},{"key":"2025073111431943000_8.1.e000940.3","doi-asserted-by":"publisher","DOI":"10.1002\/sim.2712"},{"key":"2025073111431943000_8.1.e000940.4","doi-asserted-by":"publisher","DOI":"10.1179\/175709208X334614"},{"key":"2025073111431943000_8.1.e000940.5","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605062"},{"key":"2025073111431943000_8.1.e000940.6","unstructured":"The chronic condition warehouse. chronic conditions data Warehouse: CCW chronic condition algorithms. Available: https:\/\/www.ccwdata.org\/web\/guest\/condition-categories [Accessed 23 Jan 2017]."},{"key":"2025073111431943000_8.1.e000940.7","unstructured":"The Medicare Payment Advisory Commission . MedPAC Data book: Beneficiaries dually eligible for Medicare and Medicaid - January 2016, 2016. Available: http:\/\/www.medpac.gov\/docs\/default-source\/publications\/january-2016-medpac-and-macpac-data-book-beneficiaries-dually-eligible-for-medicare-and-medicaid.pdf?sfvrsn=0 [Accessed 23 Jan 2017]."},{"key":"2025073111431943000_8.1.e000940.8","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-010-9451-7"},{"key":"2025073111431943000_8.1.e000940.9","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e3181b7fbbb"},{"key":"2025073111431943000_8.1.e000940.10","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/70.1.41"},{"key":"2025073111431943000_8.1.e000940.11","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00057010"},{"key":"2025073111431943000_8.1.e000940.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa072761"},{"key":"2025073111431943000_8.1.e000940.13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.330.7499.1059"},{"key":"2025073111431943000_8.1.e000940.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61969-3"},{"key":"2025073111431943000_8.1.e000940.15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2009.01125.x"},{"key":"2025073111431943000_8.1.e000940.16","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.25.12.2244"},{"key":"2025073111431943000_8.1.e000940.17","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-008-0090-3"},{"key":"2025073111431943000_8.1.e000940.18","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0719"},{"key":"2025073111431943000_8.1.e000940.19","unstructured":"Krebs R . Metformin: a fountain of youth pill for only five Cents? natural stacks. Available: https:\/\/www.naturalstacks.com\/blogs\/news\/metformin [Accessed 16 Nov 2018]."},{"key":"2025073111431943000_8.1.e000940.20","doi-asserted-by":"publisher","DOI":"10.2337\/cd18-0105"},{"key":"2025073111431943000_8.1.e000940.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjd.2015.02.002"},{"key":"2025073111431943000_8.1.e000940.22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67528-9"},{"key":"2025073111431943000_8.1.e000940.23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j2499"},{"key":"2025073111431943000_8.1.e000940.24","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.029190"},{"key":"2025073111431943000_8.1.e000940.25","unstructured":"FDA . Fda drug safety communication: FDA revises label of diabetes drug canagliflozin (Invokana, Invokamet) to include updates on bone fracture risk and new information on decreased bone mineral density | FDA. Available: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-revises-label-diabetes-drug-canagliflozin-invokana-invokamet [Accessed 12 Sep 2019]."},{"key":"2025073111431943000_8.1.e000940.26","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1111\/dom.13255","article-title":"SGLT-2 inhibitors and the risk of lower-limb amputation: is this a class effect?","volume":"20","author":"Khouri","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2025073111431943000_8.1.e000940.27","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0b013e32835edb32"},{"key":"2025073111431943000_8.1.e000940.28","doi-asserted-by":"crossref","unstructured":"Hidayat K , Du X , Shi B-M . Risk of fracture with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in real-world use: systematic review and meta-analysis of observational studies. Osteoporos Int 2019:1\u201318.","DOI":"10.1007\/s00198-019-04968-x"},{"key":"2025073111431943000_8.1.e000940.29","doi-asserted-by":"publisher","DOI":"10.7326\/M15-3016"},{"key":"2025073111431943000_8.1.e000940.30","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.23.2981"},{"key":"2025073111431943000_8.1.e000940.31","unstructured":"Ryan P , Schuemie M , Suchard M . Legend: clinical insights for hypertension. Bethesda, MD: OHDSI Symposium, 2018. https:\/\/www.ohdsi.org\/wp-content\/uploads\/2018\/10\/OHDSI-2018-Symposium-LEGEND-HTN-Suchard-12oct2018-2.pdf"},{"key":"2025073111431943000_8.1.e000940.32","doi-asserted-by":"crossref","first-page":"224S","DOI":"10.1097\/01.ASN.0000032544.37147.AE","article-title":"Renal and cardiovascular protection in type 2 diabetes mellitus: angiotensin II receptor blockers","volume":"13 Suppl 3","author":"Deferrari","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"2025073111431943000_8.1.e000940.33","doi-asserted-by":"publisher","DOI":"10.1016\/S1388-9842(00)00084-2"},{"key":"2025073111431943000_8.1.e000940.34","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02527-7"},{"key":"2025073111431943000_8.1.e000940.35","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ahj.2018.12.007","article-title":"Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: a systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants","volume":"210","author":"Yebyo","year":"2019","journal-title":"Am Heart J"},{"key":"2025073111431943000_8.1.e000940.36","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.atherosclerosis.2019.01.030","article-title":"Statins for primary prevention in adults aged 75 years and older: a nationwide population-based case-control study","volume":"283","author":"Jun","year":"2019","journal-title":"Atherosclerosis"},{"key":"2025073111431943000_8.1.e000940.37","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1111\/jgs.16060","article-title":"Statin Use Over 65\u2009Years of Age and All-Cause Mortality: A 10-Year Follow-Up of 19 518 People","volume":"67","author":"Eilat-Tsanani","year":"2019","journal-title":"J Am Geriatr Soc"},{"key":"2025073111431943000_8.1.e000940.38","first-page":"25709","article-title":"AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol","volume":"2018","author":"Grundy","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2025073111431943000_8.1.e000940.39","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.15450"},{"key":"2025073111431943000_8.1.e000940.40","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh104"}],"container-title":["BMJ Open Diabetes Research &amp; Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjdrc-2019-000940","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T18:43:30Z","timestamp":1753987410000},"score":1,"resource":{"primary":{"URL":"https:\/\/drc.bmj.com\/lookup\/doi\/10.1136\/bmjdrc-2019-000940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,4,26]]},"published-print":{"date-parts":[[2020,4]]}},"alternative-id":["10.1136\/bmjdrc-2019-000940"],"URL":"https:\/\/doi.org\/10.1136\/bmjdrc-2019-000940","relation":{},"ISSN":["2052-4897"],"issn-type":[{"value":"2052-4897","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4]]}}}